Maxion Therapeutics announced it has been awarded a £2m ($2.5m) grant from Innovate UK as part of a biomedical R&D funding competition. The funds will support Maxion’s KnotBody platform to develop antibodies to treat autoimmune diseases.

Antibody-based therapies provide enhanced efficacy and safety whilst reducing the need for frequent administration for autoimmune disease treatment. However, not all patients respond to treatment equally well and the therapies can lead to immunosuppression.

Cambridge, UK-based Maxion utilises miniproteins (knottins) that block ion channels. According to the company, when knottins bind with antibodies, the resulting “KnotBodies” combine the ion channel-blocking activity of knottins with targeted action of antibodies. As per the company, this allows for a longer half-life in the body and gives the ability for further biomolecular engineering.

As per Maxion, there are more than 80 types of autoimmune conditions. In the UK, approximately 4 million people live with at least one autoimmune condition, with incidence rising by 3-9% each year.

The £2m grant from UK Research and Innovation and is part of a wider £25m ($31m) investment into UK-registered projects. The funding follows a $16m Series A financing round by Maxion from LifeArc Ventures, Monograph Capital and BGF.

“KnotBody technology overcomes many of the challenges presented by conventional antibody development techniques, with an ability to specifically target ion channels linked to chronic autoimmune diseases,” said Maxion’s co-founder Dr Aneesh Karatt Vellatt.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are excited by the potential therapeutic candidates in our pipeline, and this new funding from Innovate UK will allow us to expedite their development and progress the most promising drug candidate towards clinical trials.”